Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 35 P884 | DOI: 10.1530/endoabs.35.P884

ECE2014 Poster Presentations Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) (108 abstracts)

Register of sellar tumors: RESET: diagnostics and therapy of acromegaly in Czech and Slovak Republics

Václav Hána1, Jan Švancara8, Lubomira Bandurová1, Petr Brabec8, Jan Čáp2, Viktoria Durovcova1, Eva Dvoráková9, Václav Hána1, Zuzana Jarkovská1, Peter Kentoš5, Daniel Klimeš8, Michal Krčma9, Michal Kršek1, Ivica Lazúrová6, Věra Olšovská3, Ján Podoba4, Mikuláš Pura5, Michaela Sásiková4, Karel Starý10, Jana Strenková8, Helena Šiprová3, Juraj Štěňo7, Ludmila Trejbalová4, Peter Vaňuga5, Hedviga Wagnerová6, Vladimír Weiss1, Dalibor Zeman3, Ladislav Dušek8 & Josef Marek1

13rd Department of Internal Medicine, Charles University, Prague, Czech Republic; 22nd Department of Internal Medicine, Charles University, Hradec Králové, Czech Republic; 32nd Department of Internal Medicine, Masaryk University, Brno, Czech Republic; 41st Department of Internal Medicine, Faculty Hospital, Bratislava, Slovakia; 5National Institute of Endocrinology and Diabetes, Lubochna, Slovakia; 61st Dept. of Internal Medicine, Faculty Hospital, Kosice, Slovakia; 7Neurosurgery Department, Faculty Hospital, Bratislava, Slovakia; 8Institute of Biostatistics and Analysis, Masaryk University, Brno, Czech Republic; 91st Department of Internal Medicine, Faculty Hospital, Plzen, Czech Republic; 10Department of Internal Medicine, Faculty Hospital, Brno-Bohunice, Czech Republic.

Acromegaly is usually diagnosed after several years of duration. The multimodal therapy – surgery, radiotherpy, pharmacotherapy – is necessary in the majority of patients. Register of sellar tumors (RESET) collecting data of patients from eight tertiary centers in the Czech and Slovak Republics since the year 2000 was established in 2008.

Aim of analysis: Evaluation of diagnostics of acromegaly and effectiveness of its treatment in a daily practice in CR and SR in a period 1.1.2000–3.9.2013.

Patients and results: 343 patients (185+158 from CR a SR, resp., 189 women, mean age at diagnosis 49 years; for men 46 and for women 52 years). Median time of follow-up was 39.3 months. Three quarters had macroadenoma. In the time of diagnosis 44% of patiens had arterial hypertension (38%) or diabetes mellitus (17%), respectively both (11%). Operated were 81% of patients (reoperated 5%); 93% of operations were transsfenoidal. Normalised IGF1 3 months after surgery was in 54.5% of patients with microadenoma and in 42.4% with macroadenoma. Residual hormonal activity after surgery was treated in the majority of patients with combined radiotherapy and pharmacotherapy. Irradiated were 166 patients and 91% of them underwent radiosurgery with gamma-knife. Long-term pharmacotherapy applied was with somatostatin analogs in 90, dopamine agonists in 69 and with pegvisomant in 37 patients; either alone or in combination. Patients with operation as part of the complex therapy had faster suppression of hormonal activity.

Conclusions: Acromegaly is a serious disease frequently complicated with hypertension and diabetes mellitus. 75% of patients have macroadenoma. The fastest suppression of disease activity is achieved when therapy comprise surgery, alone or in conjunction with other modalities. An individually tailored multimodal therapy is necessary in the majority of patients.

The project is supported by a grant of Novartis.

Article tools

My recent searches

No recent searches.